Stimulation of Angiogenesis with miRNA as Protection Against Acute Kidney Injury

Hospital-acquired acute kidney injury (AKI) accounts for 22% of all cases worldwide, and an estimated 50% of critically ill inpatients are estimated to suffer from AKI. AKI is associated with high rates of morbidity and mortality and causes 2 million deaths per year. Patients who recover are at a higher risk for subsequently developing chronically kidney disease (CKD); other times, the injury is so severe that it leads to end stage renal disease (ESRD). There are no definitive or effective treatments for AKI, nor are there available interventions to decrease the risk of progression to CKD after AKI.

Description

One of the hallmarks of AKI is damage to renal microvasculature, which alters endothelial function and contributes to hypoxic and inflammatory injury to the renal parenchyma. In AKI, some miRNAs appear to act pathogenically by promoting inflammation, apoptosis, and fibrosis, while others may confer protective benefits. Researchers have obtained preliminary data indicating that the absence of the miR-17~92 cluster makes cells are more susceptible to renal ischemia-reperfusion injury while miR-18a and miR-19b protects against renal IRI, providing evidence for a potential novel therapeutic approach for the treatment of acute kidney injury.

Applications

· Treating acute kidney injury

Advantages

· Novel approach to treating acute kidney injury

Invention Readiness

In vivo data in mice using mimics

IP Status

https://patents.google.com/patent/US20230323347A1

Related Publication(s)

Chiba, T., Cerqueira, D. M., Li, Y., Bodnar, A. J., Mukherjee, E., Pfister, K., Phua, Y. L., Shaikh, K., Sanders, B. T., Hemker, S. L., Pagano, P. J., Wu, Y. L., Ho, J., & Sims-Lucas, S. (2021). Endothelial-Derived miR-17∼92 Promotes Angiogenesis to Protect against Renal Ischemia-Reperfusion Injury. Journal of the American Society of Nephrology, 32(3), 553–562. https://doi.org/10.1681/asn.2020050717

Quick Facts:
Reference Number
05448
Technology Type
Therapeutic Modality
Technology Subtype
Gene Therapy - RNA
Therapeutic Areas
Nephrology
Tags
Regenerative medicine
Lead Inventor
Sunder Lucas
Department
Med-Pediatrics
All Tech Innovators
Takuto ChibaJacqueline HoSunder Sims Lucas
Technology Readiness Level
3. Initial proof of concept, in-vivo
Date Submitted
2020-07-16
Collections
Cell & Gene TherapyRegenerative Medicine